Gavin focuses on EU competition and merger control law, and aviation law and regulation, and has acted for global companies in various sectors including aviation, banking, pharmaceuticals, beverages, medical devices, mining, parcel delivery services, recorded music, manufacturing, packaging and nuclear energy. He has broad experience in all aspects of merger transactions, international cartel and horizontal agreement investigations, state aid proceedings, Article 102 TFEU (abuse of dominance) investigations as well as representing clients in litigation before the General Court of the European Court of Justice in Luxembourg to challenge European Commission decisions. Mr. Bushell has advised and trained clients around the world on creating and implementing competition compliance training programmes.
Representative Legal Matters
Represents Hitachi Ltd on its GBP 11 billion acquisition of the ABB Power Grid business before the European Commission as well as coordinating the global merger filing strategy.
Represented one of the largest German airlines and Brussels Airlines on the acquisition of Thomas Cook Airlines Belgium before several national competition authorities.
Represented Abbott Laboratories on its USD 5.8 billion acquisition of Alere Inc. before the European Commission to secure conditional Phase I clearance in the face of an active complainant and the subsequent approval of two up-front buyers.
Represented Lonza on its USD 5.5 billion acquisition of Capsugel before the European Commission to secure unconditional Phase I clearance.
Represented Safran on the sale of its Morpho Detection business to Smiths Group before the European Commission to secure conditional Phase I clearance.
Represented FedEx before the European Commission to successfully secure Phase II unconditional clearance of its EUR 4.4 billion acquisition of TNT Express after having represented FedEx before the European Commission to successfully challenge the UPS/TNT merger. Subsequently represented FedEx as intervener before the General Court in the UPS v Commission litigation.
Represented Abbott Laboratories before the European Commission to obtain conditional Phase I clearance of the sale of its Established Pharmaceutical Division in Development Markets to Mylan for USD 5.3 billion.
Represented Shanghai Jin Jiang International Hotels Group before the European Commission on its EUR 1.7 billion acquisition of the Radisson Group.
Represented Camso on its EUR 1.7 billion acquisition by Michelin.
Represented AGFA on its proposed joint venture with LHG.
Professional Associations and Memberships
- Law Society of England & Wales - Member
- Barreau de Bruxelles - A-List
- Brussels~Belgium (2002)
- England & Wales~United Kingdom (2002)
Co-author "Dow/DuPont and the Innovation Theory of Harm," The Threshold, ABA Magazine, Spring 2018
Co-author (with Bill Batchelor and Fiona Carlin), "EU Merger Control: the Dow/DuPont Theory of Innovation Harm," Client Alert, October 2017, named Best Business Article at the 2018 Concurrences Antitrust Writing Awards
Chairman, Baker McKenzie Seminar on Merger Control and Gun-Jumping after Altize, London, November 2018
Speaker, Brussels School of Competition: Innovation and Merger Control, April 2017
Moderator, “Baker McKenzie and MLex: The Impact of Innovation in Merger Control," London and New York Seminar, February 2017